Oncotarget

Research Papers:

Long noncoding RNA MEG3, a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis

Xiangrong Cui, Xuan Jing, Chunlan Long, Jie Tian and Jing Zhu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:19049-19056. https://doi.org/10.18632/oncotarget.14987

Metrics: PDF 1621 views  |   HTML 2168 views  |   ?  


Abstract

Xiangrong Cui1,2,3,*, Xuan Jing5,*, Chunlan Long1,2,3, Jie Tian4, Jing Zhu1,2,3

1Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, 400014, China

2China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, 400014, China

3Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China

4Cardiovascular Department (Internal Medicine), Children's Hospital of Chongqing Medical University, Chongqing, 400014, China

5Clinical Laboratory, Shanxi Province People’s Hospital, Shanxi, 030000, China

*These authors contributed equally to this work

Correspondence to:

Jing Zhu, email: [email protected]

Keywords: lncRNA, MEG3, clinical outcome, carcinoma, meta-analysis

Received: December 05, 2016     Accepted: January 11, 2017     Published: February 01, 2017

ABSTRACT

Numerous studies have demonstrated that the expression level of maternally expressed gene 3 (MEG3) was lost in various cancers. Low expression of MEG3 is associated with an increased risk of metastasis and a poor prognosis in cancer patients. This meta-analysis investigated the association between MEG3 levels and distant metastasis (DM), lymph node metastasis (LNM), overall survival (OS), and recurrence-free survival (RFS) of cancer patients. A total of 536 participants from 9 articles were finally enrolled. The results showed a significant negative association between MEG3 levels and DM (OR = 2.16, 95% CI = 0.99–4.71, P = 0.05, fixed-effect), and it could also predict poor OS (HR = 0.43, 95% CI = 0.15–1.24, P = 0.006, fixed-effect) and RFS (HR = 0.52, 95% CI = 0.29–0.92, P = 0.02, fixed-effect) in cancer patients. In conclusion, this meta-analysis indicated that MEG3 might serve as a potential novel biomarker for indicating the clinical outcomes in human cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14987